Entendiendo las terapias actuales en melanoma metastásico

• Rocío Rodríguez ^[1] ; Angela Parra ^[1] ; Sergio González ^[1] ; Montserrat Molgó ^[1] ; Nicolás Droppelmann ^[1] ; Francisco Acevedo ^[1] ; José Peña ^[1] ; Pablo Uribe ^[1]
  1. [1] Pontificia Universidad Católica de Chile

     Pontificia Universidad Católica de Chile

     Santiago, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 144, Nº. 11, 2016, págs. 1448-1458
• Idioma: español
• Títulos paralelos:
  • Understanding current therapies in metastatic melanoma
• Enlaces
  • Texto completo
• Resumen

  • Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-L1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PD-L1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.